[{"id":"5e25c190-7b84-4684-81a8-f9c1a3e15bde","acronym":"","url":"https://clinicaltrials.gov/study/NCT03000257","created_at":"2021-01-17T17:43:13.957Z","updated_at":"2024-07-02T16:36:12.444Z","phase":"Phase 1","brief_title":"A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors","source_id_and_acronym":"NCT03000257","lead_sponsor":"AbbVie","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • budigalimab (ABBV-181) • Rova-T (rovalpituzumab tesirine)"],"overall_status":"Completed","enrollment":" Enrollment 182","initiation":"Initiation: 12/14/2016","start_date":" 12/14/2016","primary_txt":" Primary completion: 03/29/2022","primary_completion_date":" 03/29/2022","study_txt":" Completion: 03/29/2022","study_completion_date":" 03/29/2022","last_update_posted":"2022-04-14"},{"id":"680d552b-cfb3-4df6-aa58-07d9a19c5ba6","acronym":"TRINITY","url":"https://clinicaltrials.gov/study/NCT02674568","created_at":"2021-01-18T13:02:22.290Z","updated_at":"2024-07-02T16:36:27.176Z","phase":"Phase 2","brief_title":"Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer","source_id_and_acronym":"NCT02674568 - TRINITY","lead_sponsor":"AbbVie","biomarkers":" DLL3","pipe":" | ","alterations":" DLL3 expression","tags":["DLL3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e DLL3 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rova-T (rovalpituzumab tesirine)"],"overall_status":"Completed","enrollment":" Enrollment 342","initiation":"Initiation: 01/25/2016","start_date":" 01/25/2016","primary_txt":" Primary completion: 10/19/2018","primary_completion_date":" 10/19/2018","study_txt":" Completion: 10/19/2018","study_completion_date":" 10/19/2018","last_update_posted":"2021-07-30"},{"id":"34ae103a-b412-45f5-90e9-91f1d4a0633e","acronym":"TAHOE","url":"https://clinicaltrials.gov/study/NCT03061812","created_at":"2021-01-18T15:04:51.416Z","updated_at":"2024-07-02T16:36:34.211Z","phase":"Phase 3","brief_title":"Study Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advanced or Metastatic Small Cell Lung Cancer With High Levels of Delta-like Protein 3 (DLL3) and Who Have First Disease Progression During or Following Front-line Platinum-based Chemotherapy (TAHOE)","source_id_and_acronym":"NCT03061812 - TAHOE","lead_sponsor":"AbbVie","biomarkers":" DLL3","pipe":" | ","alterations":" DLL3 expression","tags":["DLL3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e DLL3 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e topotecan • Rova-T (rovalpituzumab tesirine)"],"overall_status":"Completed","enrollment":" Enrollment 444","initiation":"Initiation: 04/11/2017","start_date":" 04/11/2017","primary_txt":" Primary completion: 02/12/2020","primary_completion_date":" 02/12/2020","study_txt":" Completion: 02/12/2020","study_completion_date":" 02/12/2020","last_update_posted":"2021-02-23"},{"id":"b30f2f33-84b5-4059-90ef-7847c753b221","acronym":"","url":"https://clinicaltrials.gov/study/NCT03334487","created_at":"2021-01-18T16:27:54.762Z","updated_at":"2024-07-02T16:37:04.374Z","phase":"Phase 3b","brief_title":"Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer","source_id_and_acronym":"NCT03334487","lead_sponsor":"AbbVie","biomarkers":" DLL3","pipe":" | ","alterations":" DLL3 expression","tags":["DLL3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e DLL3 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rova-T (rovalpituzumab tesirine)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 03/15/2018","start_date":" 03/15/2018","primary_txt":" Primary completion: 12/20/2018","primary_completion_date":" 12/20/2018","study_txt":" Completion: 12/20/2018","study_completion_date":" 12/20/2018","last_update_posted":"2018-12-26"}]